“Today, the U.S. Food and Drug Administration approved Retevmo (selpercatinib) capsules to treat three types of tumors – non-small cell lung cancer, medullary thyroid cancer and other types of thyroid cancers – in patients whose tumors have an alteration (mutation or fusion) in a specific gene (RET or “rearranged during transfection”). Retevmo is the first therapy approved specifically for cancer patients with the RET gene alterations.”
View the whole story here: https://www.prnewswire.com/news-releases/fda-approves-first-therapy-for-patients-with-lung-and-thyroid-cancers-with-a-certain-genetic-mutation-or-fusion-301056045.html